Three Stocks Nobody's Talking About That Deserve Your Attention Right Now
Small caps, big potential, zero hype — the way it should be
Everyone's glued to oil headlines and Strait of Hormuz drama. Cool. Meanwhile, some genuinely interesting small-cap stories are flying completely under the radar — which is exactly where the good stuff usually hides.
First up: $CELH's recent chaos exposed something interesting about the energy drink category broadly. The Morningstar AI moat analysis covering 132 companies quietly flagged that enterprise software and IT services are getting wrecked — firms like $ADBE, $WDAY, $ADP, and $PAYX all saw moat downgrades. That's a crowded short thesis, sure, but it points to a real structural shift: whoever builds the picks-and-shovels layer below those app vendors wins. Think niche SaaS infrastructure plays with sticky switching costs and sub-$5B market caps — the ones Morningstar's 132-company list didn't bother covering because they're too small to matter. Yet.
The China biotech angle from IBD is equally compelling — ADC platforms, bispecifics, CAR-T — Western pharma (Lilly, Pfizer, AstraZeneca) is already licensing aggressively. The domestic ADC-adjacent names with actual clinical data and market caps under $3B are exactly the kind of thing that gets quietly acquired before anyone notices. The quiet ones always get the bag.